tumor volume of 100 mm 3 range 50 200 mm 3 at 34 days post implantation 8 10 mice were randomly assigned into each of 3 treatment groups 7bd 33 11a 1a245 6 test antibodies or isotype control antibody was administered intraperitoneally with 15 mg kg of antibodies at a volume of 150 microliters after dilution from the stock concentration with a diluent that contained 2 7 mm kcl 1 mm kh 2 po 4 137 mm nacl and 20 mm na 2 hpo 4 the antibodies were then administered 3 times per week for 10 doses in total in the same fashion until day 56 post implantation tumor growth was measured about every seventh day with calipers until day 59 post implantation or until individual animals reached the ccac end points body weights of the animals were recorded for the duration of the study at the end of the study all animals were euthanised according to ccac guidelines in continuation from ser no 10 348 284 there was a post treatment tumor burden reduction fig2 and survival benefit fig3 associated with treatment with either 7bd 33 11a or 1a245 6 at day 80 23 days post treatment both 7bd 33 11a and 1a245 6 had decreased mean tumor volumes compared to isotype control treatment 83 p 0 001 and 35 percent p 0 135 respectively a cox proportional model was used to compare the hazard risk rates in the different groups in this method the hazard rate of every group is compared with the hazard of the isotype control group at approximately 60 days post treatment.